Bone Health Technologies (BHT) has unveiled Osteoboost, a ground-breaking device, at the esteemed Endo 2023 conference. Osteoboost is carving a new path in treating low bone mass in postmenopausal women.
The double-blind, sham-controlled trial demonstrated an astounding efficacy of Osteoboost in curbing the decline in bone strength and density. Subjects donning Osteoboost reported an 82% decline in the loss of bone strength and an 85% decrease in bone density loss. The device employs targeted vibration to the lumbar spine and hips, showcasing a tremendous promise in managing osteopenia.
Laura Bilek, Ph.D., highlighted the critical need for innovative technologies like Osteoboost to equip women in their battle against bone loss. Bone Health Technologies continues to pioneer forward, bringing forth solutions with no serious side effects.